Skip to Main Content

Paper Details

CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.
JCI Insight
0
2024
ARV825, BET, H3K27ac, PHGDH, PSAT1, Patients, SGOC, bromodomain, cancer, cholangiocarcinoma, glycine, mTOR, one carbon, serine, serine glycine, tumor, underserved disease, xenograft model
Author NameAffiliation
Jason T HuseUniversity of Texas MD Anderson Cancer Center
Traver HartUniversity of Texas MD Anderson Cancer Center
Lawrence N KwongUniversity of Texas MD Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2